PureTech Health (LON:PRTC) Shares Up 14% - What's Next?

Key Points

• PureTech Health plc's stock surged 14% during mid-day trading, reaching a high of GBX 123.80 ($1.68) and closing at GBX 121.30 ($1.64), with trading volume significantly increasing by 218% from its average.
• The company has a market capitalization of £293.65 million and notable financial ratios, including a price-to-earnings ratio of 714.71 and a debt-to-equity ratio of 45.82.
• Insider Bharatt Chowrira purchased 167,739 shares at GBX 1 per share, acquiring a total stake of 13.13% in the company.

Shares of PureTech Health plc (LON:PRTC - Get Free Report) were up 14% during mid-day trading on Friday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.30 ($1.64). Approximately 2,367,023 shares changed hands during trading, an increase of 218% from the average daily volume of 745,025 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Stock Up 4.2%

The company's fifty day moving average price is GBX 129.31 and its 200-day moving average price is GBX 129.65. The stock has a market capitalization of £303.07 million, a PE ratio of 737.65 and a beta of 1.02. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82.

Insider Activity

In other PureTech Health news, insider Bharatt Chowrira bought 167,739 shares of the stock in a transaction dated Thursday, July 3rd. The stock was purchased at an average cost of GBX 1 per share, for a total transaction of £1,677.39. Insiders own 13.13% of the company's stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.